Endpoint Sample Clauses

Endpoint. You can access the web service from the browser, with or without pre- GetContactIdByName GetContactIdByName endpoint of the web service from the browser and pass the contact name in the xxxx://xxxxxxxxx.xxx/0/ServiceModel/UsrAnonymousConfigurationService/GetContactIdByName?Name=And Request string that contains the name of the existing contact Name If Creatio finds the contact from the return the contact ID value. If Creatio finds no contacts from the return an empty string. parameter in the database, the GetContactIdByNameResult Name parameter in the database, the property will GetContactIdByNameResult property will xxxx://xxxxxxxxx.xxx/0/ServiceModel/UsrAnonymousConfigurationService/GetContactIdByName?Name=And Request string that contains the name of a non-existing contact Call a custom web service from the front- end Medium
Endpoint. The [**] will be judged on the basis of [**]. ID Vaccines Immunogenicity markers will include, but will not be restricted to: [**]. The nature of a chosen marker(s) will depend on [**]. Whenever possible, [**] will be assessed for [**]. Cancer Vaccines Immunogenicity markers will include, but will not be restricted to: [**]. AD Vaccines The markers will primarily include: [**]. Other factors that will [**].
Endpoint. Figure 71: General ComVantage access control architecture As shown in the figure above, the initial ComVantage high level architecture consists of three main blocks:  LD Network Access Manager: this block is in charge of deciding if the access will be granted or not. The information about the request will be stored, together with the decision adopted in the Access Log repository.  Linked Data information Access Manager: this block is responsible of showing the user all the resources that are accessible to the user’s role. It is also responsible of managing the exceptional and temporary access requests.  Trusted Network and Policy management: this block maintains updated the common ComVantage information, such as the CV roles, CV collaborative policies and CV collaborator’s list. All this information is stored in the Collaborative Policy Storage for each domain. In addition, an authentication component is defined, which is in charge of allowing or denying access to the access control module. It is also assumed that each user application has to be authenticated towards its own domain but this is out of scope of the Access Control model. In order to implement the access control addressed in the LD Network Access Manager block, two different approaches are proposed. The first one takes the access control decision based on the content of the SPARQL query. The second one makes the decision only on the base of the data source accessed. That is, with the first approach we do not care about the data structure, as we only have to analyse whether the query is authorized or not. With the second approach, we do not care about the received query, as we generate different views of the information in the different endpoints based on roles and only control that applications access to the different endpoints to which they have permissions depending on their role. Therefore, both approaches fit with this architecture shown. The only differ in the way the block LD Network Access Manager is implemented. The rest of the blocks apply to both of them. In order to better explain the architecture and operation of the security model, the common modules will be explained first. Afterwards, the different approaches to implement the LD Network Manager will be explained.
Endpoint. Any device capable of being connected, either physically or wirelessly to a network, and accepts communications back and forth across the network. Endpoints include, but are not limited to, computers, servers, tablets, mobile devices, or any similar network enabled device.
Endpoint. Frequency and severity of adverse events categorized using the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).
Endpoint. 6.26.2 UK fixed line geographic number (01 or 02) 6.26.3 UK 03, 080x, 050x number

Related to Endpoint

  • Study Resolution of issues surrounding Keno facility are an important part of achieving the overall goals of this Settlement. Accordingly, the Secretary, in consultation with affected Parties, shall study issues specific to the Keno facility, with specific focus on addressing water quality, fish passage, transfer of title to the Keno facility from PacifiCorp to Interior, future operations and maintenance, and landowner agreements. The study of the Keno facility will be designed with the goals of addressing these issues and maintaining the benefits the dam currently provides.

  • Evaluation Criteria 5.2.1. The responses will be evaluated based on the following: (edit evaluation criteria below as appropriate for your project)

  • Clinical Studies The preclinical studies and tests and clinical trials described in the Registration Statement, the Time of Sale Prospectus and the Prospectus were, and, if still pending, are being conducted in all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of such studies, tests and trials, and the results thereof, contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus are accurate and complete in all material respects; the Company is not aware of any tests, studies or trials not described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the results of which reasonably call into question the results of the tests, studies and trials described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and the Company has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable authority or any institutional review board or comparable authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials.

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Screening All drug screening tests shall be conducted by medical laboratories certified by the Department of Health and Human Services or certified by a DHHS recognized certification program. No test shall be considered positive until it has been confirmed by a Gas Chromatography/Mass Spectrometry full scan test or its equivalent. The procedures utilized by the City and testing laboratory shall include an evidentiary chain of custody control. All procedures shall be outlined in writing and this outline shall be followed in all situations arising under this Article. The split sample method of collection shall be used and shall follow prescribed testing procedures. Collection of samples for all random testing shall take place in the police department.

  • Evaluation Cycle Goal Setting and Development of the Educator Plan

  • Organ Transplants This plan covers organ and tissue transplants when ordered by a physician, is medically necessary, and is not an experimental or investigational procedure. Examples of covered transplant services include but are not limited to: heart, heart-lung, lung, liver, small intestine, pancreas, kidney, cornea, small bowel, and bone marrow. Allogenic bone marrow transplant covered healthcare services include medical and surgical services for the matching participant donor and the recipient. However, Human Leukocyte Antigen testing is covered as indicated in the Summary of Medical Benefits. For details see Human Leukocyte Antigen Testing section. This plan covers high dose chemotherapy and radiation services related to autologous bone marrow transplantation to the extent required under R.I. Law § 27-20-60. See Experimental or Investigational Services in Section 3 for additional information. To speak to a representative in our Case Management Department please call 1-401- 000-0000 or 1-888-727-2300 ext. 2273. The national transplant network program is called the Blue Distinction Centers for Transplants. SM For more information about the Blue Distinction Centers for TransplantsSM call our Customer Service Department or visit our website. When the recipient is a covered member under this plan, the following services are also covered: • obtaining donated organs (including removal from a cadaver); • donor medical and surgical expenses related to obtaining the organ that are integral to the harvesting or directly related to the donation and limited to treatment occurring during the same stay as the harvesting and treatment received during standard post- operative care; and • transportation of the organ from donor to the recipient. The amount you pay for transplant services, for the recipient and eligible donor, is based on the type of service.

  • Constructability Review The Engineer shall provide Independent Quality Review of the constructability PS&E sets. The Engineer shall perform constructability reviews at major project design milestones (e.g. 30%, 60%, 90%, and final plan) to identify potential constructability issues and options that would provide substantial time savings during construction. The constructability review must be performed for all roadway and structural elements such as Sequence of Work/Traffic Control, Drainage (Temporary and Permanent), Storm Water Pollution Prevention Plan (SW3P), Environmental Permits, Issues and Commitments (EPIC) addressed, identify Utility conflicts; ensuring accuracy and appropriate use of Items, Quantities, General Notes, Standard and Special Specifications, Special Provisions, Contract Time/Schedule, Standards; and providing detailed comments in an approved format. Reviews must be captured in a Constructability Log identifying areas of concern and potential conflict. The Engineer shall provide the results of all Constructability reviews and recommendations to the State at major project design milestone submittals.

  • Outcomes Provider’s services will result in the following:

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s Knowledge, on behalf of the Company that are described in the SEC Filings were and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the U.S. Food and Drug Administration (the “FDA”) or any foreign governmental body exercising comparable authority, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, and all applicable laws and regulations; the descriptions of the studies, tests and preclinical and clinical trials conducted by or, to the Company’s Knowledge, on behalf of the Company, and the results thereof, contained in the SEC Filings are accurate and complete in all material respects; the Company is not aware of any other studies, tests or preclinical and clinical trials, the results of which call into question the results described in the SEC Filings; and the Company has not received any notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board requiring the termination, suspension, material modification or clinical hold of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.